RGNX
Price:
$8.77
Market Cap:
$433.44M
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for...[Read more]
Industry
Biotechnology
IPO Date
2015-09-17
Stock Exchange
NASDAQ
Ticker
RGNX
According to REGENXBIO Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.53. This represents a change of 12.34% compared to the average of 3.14 of the last 4 quarters.
The mean historical Current Ratio of REGENXBIO Inc. over the last ten years is 9.06. The current 3.53 Current Ratio has changed 3.79% with respect to the historical average. Over the past ten years (40 quarters), RGNX's Current Ratio was at its highest in in the September 2015 quarter at 40.60. The Current Ratio was at its lowest in in the September 2014 quarter at 0.
Average
9.06
Median
8.09
Minimum
0.33
Maximum
27.23
Discovering the peaks and valleys of REGENXBIO Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 8.16%
Maximum Annual Current Ratio = 27.23
Minimum Annual Increase = -64.54%
Minimum Annual Current Ratio = 0.33
Year | Current Ratio | Change |
---|---|---|
2023 | 2.57 | -19.37% |
2022 | 3.19 | -19.80% |
2021 | 3.98 | -39.03% |
2020 | 6.52 | -36.34% |
2019 | 10.25 | -32.76% |
2018 | 15.24 | 30.95% |
2017 | 11.64 | 20.50% |
2016 | 9.66 | -64.54% |
2015 | 27.23 | 8.16% |
2014 | 0.33 | -30.46% |
The current Current Ratio of REGENXBIO Inc. (RGNX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.25
5-year avg
5.30
10-year avg
9.06
REGENXBIO Inc.’s Current Ratio is less than Day One Biopharmaceuticals, Inc. (14.62), less than Replimune Group, Inc. (13.46), greater than Mirum Pharmaceuticals, Inc. (3.28), less than Rocket Pharmaceuticals, Inc. (7.79), less than Avidity Biosciences, Inc. (15.78), less than uniQure N.V. (7.36), less than Protagonist Therapeutics, Inc. (13.73), less than Pliant Therapeutics, Inc. (14.47), less than Immunocore Holdings plc (5.17), less than Revolution Medicines, Inc. (15.42), less than Monte Rosa Therapeutics, Inc. (6.56), less than Stoke Therapeutics, Inc. (6.67), less than AN2 Therapeutics, Inc. (10.61), less than Passage Bio, Inc. (7.67), less than 4D Molecular Therapeutics, Inc. (28.48), less than Crinetics Pharmaceuticals, Inc. (16.09), less than LianBio (10.06), less than Kezar Life Sciences, Inc. (9.58),
Company | Current Ratio | Market cap |
---|---|---|
14.62 | $1.50B | |
13.46 | $820.54M | |
3.28 | $1.93B | |
7.79 | $1.53B | |
15.78 | $5.25B | |
7.36 | $270.27M | |
13.73 | $2.75B | |
14.47 | $882.53M | |
5.17 | $1.56B | |
15.42 | $9.32B | |
6.56 | $543.76M | |
6.67 | $685.47M | |
10.61 | $32.38M | |
7.67 | $37.06M | |
28.48 | $425.11M | |
16.09 | $5.11B | |
10.06 | $34.47M | |
9.58 | $52.10M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like REGENXBIO Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like REGENXBIO Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is REGENXBIO Inc.'s Current Ratio?
How is the Current Ratio calculated for REGENXBIO Inc. (RGNX)?
What is the highest Current Ratio for REGENXBIO Inc. (RGNX)?
What is the 3-year average Current Ratio for REGENXBIO Inc. (RGNX)?
What is the 5-year average Current Ratio for REGENXBIO Inc. (RGNX)?
How does the current Current Ratio for REGENXBIO Inc. (RGNX) compare to its historical average?